Cooperative Agreement UH2CA271205
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $251K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Connecticut, USA
Similar Awards
- This federal Project Grant award of $672,371.00 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research at Yale University to develop ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics. The project aims to improve the identification of tumor-specific antigens (TSAs) to support the development of effective cancer immunotherapies. The award has a performance period from September 1, 2025...
- This National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) Project Grant award of $683,089 to the Sloan-Kettering Institute for Cancer Research supports the development of an improved, interpretable deep learning algorithm called DeepLIIF for more reproducible and accurate PD-L1 immunohistochemistry (IHC) biomarker quantification. The goal is to leverage virtual multiplex immunofluorescence (MPIF) restaining and large, diverse datasets across lung and bladder cancers to...
- This Project Grant award of $124,134 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms of pathogenesis and treatment response in immune checkpoint inhibitor-induced colitis. The research aims to define the role of specific T cell subsets recruited from circulation in promoting inflammation and mediating therapeutic response in this condition, which can occur in up to 40% of cancer patients receiving immune checkpoint...
- This Cooperative Agreement award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The $692,491 award, effective May 1, 2025 through April 30, 2030, will allow the University of Chicago to explore cancer-specific early epigenetic marks in circulating cell-free DNA and develop a highly sensitive...
- This $386,279 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a microfluidic device for personalized immunotherapy screening on core needle biopsies from cancer patients. The project will: Create a "core needle biopsy" microfluidic cassette and protocols for functional immune assays, and Validate the microfluidic approach for screening immune checkpoint blockade therapy using core needle biopsies from...
- The National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), has awarded a $398,398 Cooperative Agreement to Baylor College of Medicine to advance protein isoform analysis through an integrated computational framework. The project aims to address challenges in accurately identifying and quantifying protein isoforms from mass spectrometry-based proteomic data, which is critical for understanding cancer biology and developing targeted therapies. The award, with a...
- This Cooperative Agreement award for $310,185.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by New York University School of Medicine to analytically and clinically validate an Epic 900K V2 array-based methylation assay for predicting recurrence in stage II melanoma. The project aims to refine and validate a 13-probe signature that was previously found to accurately identify melanoma recurrence and mortality among stage II...
- This federal Project Grant award of $418,176 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel approach called "Programmable Nucleic Acid Cytometry" at the Sloan-Kettering Institute for Cancer Research. The project aims to advance this innovative method for profiling rare cell populations from tumors and tissues, which offers advantages over traditional antibody-based cell isolation techniques. The work will...
- The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...